EHA 2021 | The role of transplant in myeloma in 2021
Surbhi Sidana
• 7 Jun 2021
Surbhi Sidana, MD, Stanford University, Stanford, CA, talks on the future role of transplant in multiple myeloma, highlighting data from the IFM2009 trial (NCT01191060) which showed that transplant achieved superior measurable residual disease (MRD)-negativity rates and progression-free survival, and data from the FORTE trial (NCT02203643), which demonstrated progression-free survival and sustained MRD-negativity in patients who receive upfront transplant. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
